Last reviewed · How we verify
0.45%NaCl
0.45% sodium chloride solution provides isotonic fluid replacement to maintain electrolyte balance and hydration.
0.45% sodium chloride solution provides isotonic fluid replacement to maintain electrolyte balance and hydration. Used for Fluid and electrolyte replacement in dehydration, Maintenance fluid therapy in hospitalized patients, Vehicle for intravenous medication administration.
At a glance
| Generic name | 0.45%NaCl |
|---|---|
| Also known as | Hypotonic saline |
| Sponsor | Hamilton Health Sciences Corporation |
| Drug class | Intravenous fluid / Electrolyte solution |
| Modality | Small molecule |
| Therapeutic area | Supportive Care / Fluid Management |
| Phase | Phase 3 |
Mechanism of action
This is a physiologic saline solution containing 0.45% sodium chloride (hypotonic relative to plasma), used for intravenous fluid administration. It helps restore intravascular volume, maintain electrolyte homeostasis, and support cellular hydration in patients with fluid deficits or dehydration. The solution is designed to be compatible with blood osmolarity and is commonly used as a maintenance or replacement fluid in clinical settings.
Approved indications
- Fluid and electrolyte replacement in dehydration
- Maintenance fluid therapy in hospitalized patients
- Vehicle for intravenous medication administration
Common side effects
- Hyperchloremic acidosis
- Hyponatremia (with prolonged use)
- Phlebitis at infusion site
- Fluid overload
Key clinical trials
- Study on Allopregnanolone and Depression in Perimenopausal Women (PHASE4)
- A Phase 1 Study of the Safety and Tolerability of Single and Multiple Ascending Doses of BWC0977 in Healthy Volunteers (PHASE1)
- NAC vs Placebo on Opioid Use for Hysterectomy (PHASE3)
- Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (PHASE2)
- Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO) (PHASE2)
- A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism (PHASE2)
- Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD (NA)
- Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.45%NaCl CI brief — competitive landscape report
- 0.45%NaCl updates RSS · CI watch RSS
- Hamilton Health Sciences Corporation portfolio CI